Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2020 Sep 14

PMID 32923848

Citations 14

Authors

Lori J Wirth

Takashi Kohno

Hibiki Udagawa

Shingo Matsumoto

Genichiro Ishii

Kevin Ebata

Brian B Tuch

Edward Y Zhu

Michele Nguyen

Steve Smith

Lauren M Hanson

Michael R Burkard

LouAnn Cable

James F Blake

Kevin R Condroski

Barbara J Brandhuber

Steve Andrews

S Michael Rothenberg

Koichi Goto

Affiliations

Soon will be listed here.

Citing Articles

Mechanisms of resistance to RET-directed therapies.

Clifton-Bligh R Endocr Relat Cancer. 2024; 32(2).

PMID: 39655713 PMC: 11798414. DOI: 10.1530/ERC-24-0224.

Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies.

Ou X, Gao G, Habaz I, Wang Y MedComm (2020). 2024; 5(9):e694.

PMID: 39184861 PMC: 11344283. DOI: 10.1002/mco2.694.

Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.

Chen W, Dream S, Leung P, Wu P, Wong S, Park J NPJ Precis Oncol. 2024; 8(1):39.

PMID: 38378752 PMC: 10879150. DOI: 10.1038/s41698-024-00536-7.

Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.

Clark L, Fisher G, Brook S, Patel S, Arkenau H Cancers (Basel). 2024; 16(1).

PMID: 38201460 PMC: 10778005. DOI: 10.3390/cancers16010031.

-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity.

Desilets A, Repetto M, Yang S, Sherman E, Drilon A Cancers (Basel). 2023; 15(16).

PMID: 37627175 PMC: 10452615. DOI: 10.3390/cancers15164146.

References

Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-80. DOI: 10.1126/science.1062538. View

Nakaoku T, Kohno T, Araki M, Niho S, Chauhan R, Knowles P . A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat Commun. 2018; 9(1):625. PMC: 5809600. DOI: 10.1038/s41467-018-02994-7. View

Ji J, Oh Y, Hong M, Yun J, Lee H, Kim D . Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. PLoS Genet. 2015; 11(8):e1005467. PMC: 4546689. DOI: 10.1371/journal.pgen.1005467. View

Elisei R, Schlumberger M, Muller S, Schoffski P, Brose M, Shah M . Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013; 31(29):3639-46. PMC: 4164813. DOI: 10.1200/JCO.2012.48.4659. View

Peters S, Camidge D, Shaw A, Gadgeel S, Ahn J, Kim D . Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):829-838. DOI: 10.1056/NEJMoa1704795. View

Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H . Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 2016; 5(1):42-50. DOI: 10.1016/S2213-2600(16)30322-8. View

Subbiah V, Velcheti V, Tuch B, Ebata K, Busaidy N, Cabanillas M . Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018; 29(8):1869-1876. PMC: 6096733. DOI: 10.1093/annonc/mdy137. View

Wells Jr S, Robinson B, Gagel R, Dralle H, Fagin J, Santoro M . Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011; 30(2):134-41. PMC: 3675689. DOI: 10.1200/JCO.2011.35.5040. View

Ou S, Ahn J, De Petris L, Govindan R, Yang J, Hughes B . Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2015; 34(7):661-8. DOI: 10.1200/jco.2015.63.9443. View

10.

Lin J, Kennedy E, Sequist L, Brastianos P, Goodwin K, Stevens S . Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2016; 11(11):2027-2032. DOI: 10.1016/j.jtho.2016.08.126. View

11.

Lee S, Lee J, Ahn M, Kim D, Sun J, Keam B . Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2016; 28(2):292-297. DOI: 10.1093/annonc/mdw559. View

12.

Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M . Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016; 17(12):1653-1660. PMC: 5143197. DOI: 10.1016/S1470-2045(16)30562-9. View

13.

Katayama R, Khan T, Benes C, Lifshits E, Ebi H, Rivera V . Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011; 108(18):7535-40. PMC: 3088626. DOI: 10.1073/pnas.1019559108. View

14.

Janne P, Yang J, Kim D, Planchard D, Ohe Y, Ramalingam S . AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015; 372(18):1689-99. DOI: 10.1056/NEJMoa1411817. View

15.

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

16.

Pao W, Miller V, Politi K, Riely G, Somwar R, Zakowski M . Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2(3):e73. PMC: 549606. DOI: 10.1371/journal.pmed.0020073. View

17.

Dagogo-Jack I, Stevens S, Lin J, Nagy R, Ferris L, Shaw A . Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. J Thorac Oncol. 2018; 13(11):e226-e227. DOI: 10.1016/j.jtho.2018.06.021. View